A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv
in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY
5031 (also known as COURAGE-ALS)